Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

164 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Role of DNA repair machinery and p53 in the testicular germ cell cancer: a review.
Romano FJ, Rossetti S, Conteduca V, Schepisi G, Cavaliere C, Di Franco R, La Mantia E, Castaldo L, Nocerino F, Ametrano G, Cappuccio F, Malzone G, Montanari M, Vanacore D, Quagliariello V, Piscitelli R, Pepe MF, Berretta M, D'Aniello C, Perdonà S, Muto P, Botti G, Ciliberto G, Veneziani BM, De Falco F, Maiolino P, Caraglia M, Montella M, De Giorgi U, Facchini G. Romano FJ, et al. Among authors: perdona s. Oncotarget. 2016 Dec 20;7(51):85641-85649. doi: 10.18632/oncotarget.13063. Oncotarget. 2016. PMID: 27821802 Free PMC article. Review.
Phase II trial of cisplatin plus prednisone in docetaxel-refractory castration-resistant prostate cancer patients.
Buonerba C, Federico P, D'Aniello C, Rescigno P, Cavaliere C, Puglia L, Ferro M, Altieri V, Perdonà S, De Placido S, Di Lorenzo G. Buonerba C, et al. Among authors: perdona s. Cancer Chemother Pharmacol. 2011 Jun;67(6):1455-61. doi: 10.1007/s00280-011-1594-z. Epub 2011 Mar 2. Cancer Chemother Pharmacol. 2011. PMID: 21365219 Clinical Trial.
Deregulation of HOX B13 expression in urinary bladder cancer progression.
Marra L, Cantile M, Scognamiglio G, Perdonà S, La Mantia E, Cerrone M, Gigantino V, Cillo C, Caraglia M, Pignata S, Facchini G, Botti G, Chieffi S, Chieffi P, Franco R. Marra L, et al. Among authors: perdona s. Curr Med Chem. 2013 Feb 1;20(6):833-9. Curr Med Chem. 2013. PMID: 23276138
EGFR mutational status in penile cancer.
Di Lorenzo G, Buonerba C, Gaudioso G, Gigantino V, Quarto G, De Domenico R, Caraglia M, Di Trolio R, Ascierto PA, De Placido S, Perdonà S, Franco R. Di Lorenzo G, et al. Among authors: perdona s. Expert Opin Ther Targets. 2013 May;17(5):501-5. doi: 10.1517/14728222.2013.783571. Epub 2013 Mar 22. Expert Opin Ther Targets. 2013. PMID: 23517177
Intravesical chemo-immunotherapy in non muscle invasive bladder cancer.
Leopardo D, Cecere SC, Di Napoli M, Cavaliere C, Pisano C, Striano S, Marra L, Menna L, Claudio L, Perdonà S, Setola S, Berretta M, Franco R, Tambaro R, Pignata S, Facchini G. Leopardo D, et al. Among authors: perdona s. Eur Rev Med Pharmacol Sci. 2013 Aug;17(16):2145-58. Eur Rev Med Pharmacol Sci. 2013. PMID: 23893180 Free article. Review.
Urotensin II receptor determines prognosis of bladder cancer regulating cell motility/invasion.
Franco R, Zappavigna S, Gigantino V, Luce A, Cantile M, Cerrone M, Facchini G, Perdonà S, Pignata S, Di Lorenzo G, Chieffi S, Vitale G, De Sio M, Sgambato A, Botti G, Yousif AM, Novellino E, Grieco P, Caraglia M. Franco R, et al. Among authors: perdona s. J Exp Clin Cancer Res. 2014 Jun 3;33(1):48. doi: 10.1186/1756-9966-33-48. J Exp Clin Cancer Res. 2014. PMID: 24893613 Free PMC article.
Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.
De Cobelli O, Buonerba C, Terracciano D, Bottero D, Lucarelli G, Bove P, Altieri V, Coman I, Perdonà S, Facchini G, Berretta M, Di Lorenzo G, Grieco P, Novellino E, Franco R, Caraglia M, Manini C, Mirone V, De Placido S, Sonpavde G, Ferro M. De Cobelli O, et al. Among authors: perdona s. Future Oncol. 2015 Nov;11(22):3091-8. doi: 10.2217/fon.15.249. Epub 2015 Sep 18. Future Oncol. 2015. PMID: 26381851 Free PMC article.
164 results